

REFERENCES for Part IV

1. Champion RH, Burton JL, Ebling FJG. Textbook of Dermatology. 5th ed. Oxford: Blackwell Scientific Publications, 1992 pp. 2164–2225, 675–676, 598–610, 1767–1769.
2. Braun-Falco O, Plewig G, Wolff HH, Winkelmann RK. Dermatology. Berlin-Heidelberg: Springer-Verlag, 1991 pp. 563–574, 348–357, 519, 546.
3. Braverman IM. Skin Signs of Systemic Disease. Philadelphia: W.B. Saunders Company, 1970 pp. 144–163.
4. Drug Facts and Comparisons. St. Louis: Wolters-Kluwer Co. 2003 ed.
5. Pavlidakey GP, et al. Chlorpromazine induced lupus-like disease. J Am Acad Dermatol 1985;13:109–115.
6. Provost TT, Reichlin M. Antinuclear antibody-negative lupus erythematosus. J Am Acad Dermatol 1981;4:84–89.
7. Trozak DJ. Topical Corticosteroid Therapy in Psoriasis. Cutis 1990;46:341–350.
8. Sontheimer RD, et al. Subacute Cutaneous Lupus Erythematosus. Arch Dermatol 1979;115:1409–1415.
9. Furner BB. Treatment of Subacute Cutaneous Lupus Erythematosus. Internat J Dermatol 1990;29:542–547.
10. Furner BB. Subacute Cutaneous Lupus Erythematosus Response to Isotretinoin. Internat J Dermatol 1990;29:587–590.
11. Callen JP, et al. Collagen-vascular disease: An update. J Am Acad Dermatol 1993;28:477–484.
12. Mitchell-Sams W, Huff JC. Practical Management of Cutaneous Lupus Erythematosus, Vasculitis, and Erythema Multiforme. Progress in Dermatology 1984;18:1–3.
13. Gilliam JN, Sontheimer MD. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol 1981;4:471–475.
14. Provost TT. Subsets in Systemic Lupus Erythematosus. J Invest Dermatol 1979;72:110–113.
15. Wechsler HL, Stavrides A. Systemic lupus erythematosus with anti-Ro antibodies: Clinical, Histologic, and immunologic findings. J Am Acad Dermatol 1982;6:73–83.
16. Provost TT, et al. The Relationship Between Anti-Ro (SS-A) Antibody-Positive Sjogren's Syndrome and Anti-Ro (SS-A) Antibody-Positive Lupus Erythematosus. Arch Dermatol 1988;124:63–71.
17. Estes D, Christian CL. The Natural History of Systemic Lupus by Prospective Analysis. Medicine 1971;50:85–95.
18. Callen JP. Serologic and clinical features of patient with discoid lupus erythematosus: Relationship of antibodies to single stranded deoxyribonucleic acid and of other antinuclear antibody subsets to clinical manifestations. J Amer Acad Dermatol 1985;13:748–755.
19. Provost TT. The relationship between discoid and systemic lupus erythematosus. Arch Dermatol 1994;130:1308–1310.
20. Ziering DO, et al. Antimalarials for children: Indications, toxicities and guidelines. J Amer Acad Dermatol 1993;28:764–770.
21. Potter B. Hydroxychloroquine. Cutis 1993;52:229–231.
22. Olansky AJ. Antimalarials and ophthalmologic safety. J Amer Acad Dermatol 1982;6:19–23.
23. Mitchell J, Rook A, Botanical Dermatology. Vancouver B.C.: Greengrass Ltd., 81–97.
24. Fisher AA. Contact Dermatitis. 2nd. ed. Philadelphia: Lea & Febiger, 1973 pp. 260–266.
25. Adams RM. Occupational Skin Disease. New York: Grune & Stratton Inc. 1983 pp. 331–337.
26. Goldstein N. The Ubiquitous Urushiols. Cutis 1968;4:679–685.
27. Guin JD, Gillis WT, Beaman JH. Recognizing the toxicodendrons (poison ivy, poison oak, and poison sumac). J Amer Acad Dermatol 1981;4:99–114.

From: *Current Clinical Practice: Dermatology Skills for Primary Care: An Illustrated Guide*
D.J. Trozak, D.J. Tennenhouse, and J.J. Russell © Humana Press, Totowa, NJ

28. Hanifin JM, Schneider LC, Leung DYM, et al. Recombinant interferon gamma therapy for atopic dermatitis. *J Amer Acad Dermatol* 1993;28:189–197.
29. Lobitz WC, Dobson RL. Physical and physiological clues for diagnosing eczema. *JAMA* 1956;161:1226–1229.
30. The guide to drug eruptions. 6th ed. Amsterdam: Free University Amsterdam; File of Medicines, 1995, p. 6.
31. Colon D. Stellate spontaneous pseudoscars: Senile and presenile forms, especially those caused by prolonged corticoid therapy. *Arch Dermatol* 1972;105:551–554.
32. Chernosky NE, Knox JM. Atrophic striae after occlusive corticosteroid therapy. *Arch Dermatol* 1964;90:15–19.
33. Macrae-Gibson NK. Red lineae distensae. *Br J Dermatol* 1952;64:315–323.
34. Elson ML. Treatment of striae distensae with topical tretinoin. *J Dermatol Surg Oncol* 1990;16:267–270.
35. Neshier G, Osborne TG, Moore TL. Parvovirus infection mimicking systemic lupus erythematosus. *Semin Arthritis Rheum* 1995;24:297.
36. Tan BB, Weald D, Strickland I, Friedmann PS. Double-blind controlled trial of effect of house-dust mite allergen avoidance on atopic dermatitis. *Lancet* 1996;347:15–18.
37. Marks JG, Fowler Jr. JF, Sheretz EF, Rietschel. Prevention of poison ivy and poison oak allergic contact dermatitis by quaternium-18 bentonite. *J Amer Acad Dermatol* 1995;33:212–216.
38. Gravelink SA, Murrell DF, Olson, EA. Effectiveness of various barrier preparations in preventing and/or ameliorating experimentally produced Toxicodendron dermatitis. *J Amer Acad Dermatol* 1992;27:182–188.
39. Provost TT. The cutaneous spectrum of lupus erythematosus. Presentation Annual Meeting Sacramento Dermatologic Society, October 18, 2003, Napa California.
40. Mutasim DF, Adams BB. A practical guide for serologic evaluation of autoimmune connective tissue diseases. *J Amer Acad Dermatol* 42, #2, part 1: 159-170.
41. Srivastava M, Rencic A, Diglio G, et al. Drug induced, Ro/SSA-positive cutaneous lupus erythematosus. *Arch Dermatol* 2003;139:45-49.
42. Williams JV, Light J, Marks JG, et al. Individual variations in allergic contact dermatitis from urushiol. *Arch Dermatol* 1999;135:1002-1003.
43. Physicians Desk Reference. Thomson 57th. ed., 2003.
44. Wolverson SE. Comprehensive Dermatologic Therapy. W B Saunders Company, 2001.
45. Bornhovd E, Burgdorf WHC, Wollenberg A. Macrolactam immunomodulators for topical treatment of inflammatory skin disorders. *J Amer Acad Dermatol* 2001;45:736-743.
46. Topical pimecrolimus (Elidel) for treatment of atopic dermatitis. *The Medical Letter* 44, issue 1131, 48-50, 2002.
47. Darvay A, Acland K, Lynn W, et al. Stria formation in two HIV-positive persons receiving protease inhibitors. *J Amer Acad Dermatol* 1999;41:467-469.
48. Borkowski TA, Sampson HA. A combined dermatology and allergy approach to the management of suspected food allergy. *Dermatological Therapy* 1996;1:38-50.
49. La Grenade L, Manns A, Fletcher V, et al. Clinical, pathologic and immunologic features of human T-lymphotropic virus type 1-associated infective dermatitis in children. *Arch Dermatol* 1998;134:439-444.